• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Tecvayli Effective in BCMA-Pretreated R/R Multiple Myeloma

by | May 17, 2024 | Uncategorized

Source: CureToday articles Tecvayli responses were found to be slightly lower in patients with relapsed/refractory myeloma treated with another BCMA-targeted therapy. Read More

Dr Baljevic on Advancements in the Management of Newly Diagnosed Multiple Myeloma

by | May 17, 2024 | Uncategorized

Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma. Read More

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

by | May 16, 2024 | Uncategorized

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma. Read More

Dr Ignatz-Hoover on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

by | May 15, 2024 | Uncategorized

James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma. Read More

Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

by | May 14, 2024 | Uncategorized

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma. Read More

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

by | May 13, 2024 | Uncategorized

Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment...
« Older Entries
Next Entries »

Recent Content

  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway
  • VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target
  • Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
  • Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
  • Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT